Comparative Pharmacology
Head-to-head clinical analysis: DACARBAZINE versus TREANDA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DACARBAZINE versus TREANDA.
DACARBAZINE vs TREANDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alkylating agent; inhibits DNA and RNA synthesis by forming covalent bonds with DNA, leading to cross-linking and strand breaks. Also inhibits purine synthesis and has some activity as a methylating agent.
Bendamustine is a bifunctional mechlorethamine derivative that forms electrophilic alkyl groups which covalently bond to DNA bases, resulting in interstrand DNA crosslinks, DNA single- and double-strand breaks, and ultimately apoptosis. It also inhibits several mitotic checkpoints and induces both apoptosis and necrosis in cancer cells.
2.4-4.5 mg/kg IV daily for 10 days every 28 days; or 250 mg/m2 IV daily for 5 days every 21 days; or 375-450 mg/m2 IV single dose every 21-28 days.
120 mg/m2 IV over 60 minutes on Days 1 and 2 of a 21-day cycle.
None Documented
None Documented
Clinical Note
moderateDacarbazine + Digoxin
"Dacarbazine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDacarbazine + Digitoxin
"Dacarbazine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDacarbazine + Deslanoside
"Dacarbazine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDacarbazine + Acetyldigitoxin
"Dacarbazine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life: 5 hours (range 3-8 h) after IV administration; biphasic decay with initial half-life ~19 min.
Terminal elimination half-life: ~36-40 minutes (active metabolite M3: ~3 hours). Short half-life supports multi-day dosing regimens; clinical effect duration is longer due to DNA alkylation.
Renal: 40-50% unchanged; hepatic: 30-50% as metabolites (primarily 5-aminoimidazole-4-carboxamide); <10% fecal.
Renal: ~50% as unchanged drug and metabolites; additional biliary/fecal elimination (non-renal clearance accounts for ~50% in humans, but specific biliary/fecal percentages not routinely quantified in clinical studies).
Category D/X
Category C
Alkylating Agent
Alkylating Agent